2002, Número S1
<< Anterior Siguiente >>
Gac Med Mex 2002; 138 (S1)
Telomerasis en Cáncer: Diagnóstico, pronóstico, e implicaciones terapéuticas
Shay JW
Idioma: Ingles.
Referencias bibliográficas: 7
Paginas: 4
Archivo PDF: 22.60 Kb.
FRAGMENTO
No tiene resumen
REFERENCIAS (EN ESTE ARTÍCULO)
Kim N-W, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PLC, Coviello GM, Wright WE, Weinrich SL, Shay JW. Specific association of human telomerase activity with immortal cells and cancer. Science 1994;266: 2011-15.
Shay JW. Telomerase in cancer: Diagnostic, prognostic and therapeutic implications. Cancer J Scientific Amer, 1998;4: 26-34.
White L, Wright WE, Shay JW. Telomerase Inhibitors. Trends in Biotechnology 2001;19:114-20.
Herbert B-S, Pitts AE, Baker SI, Hamilton SE, Wright WE, Shay JW Corey DR. Inhibition of telomerase leads to eroded telomeres, reduced proliferation, and apoptosis. Proc Natl Acad Sci USA 1999; 96:14276-81.
Herbert B-S, Wright AC, Passons CM, Ali I, Wright WE, Kopelovich L, Shay JW. Inhibition of the spontaneous immortalization of breast epithelial cells from individuals predisposed to breast cancer: Effects of chemopreventive and anti-telomerase agents. J Nat Can Inst 2001; 93: 39-45.
Damm K et al. A highly selective telomerase inhibitor limiting human cancer cell proliferation. EMBO J. 2001; 20: 6958-6968.
Vonderheide R. Telomerase as a universal tumor-associated antigen for cancer therapy. Oncogene 2002; 21: 674-679.
Texto completo
Cómo citar este artículo